<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01839149</url>
  </required_header>
  <id_info>
    <org_study_id>TRIG-05</org_study_id>
    <nct_id>NCT01839149</nct_id>
  </id_info>
  <brief_title>TI-001 (Intranasal Oxytocin) for Treatment of High Frequency Episodic Migraine and Chronic Migraine</brief_title>
  <official_title>A Phase 2, Enriched-enrollment, Randomized-withdrawal, Double-blinded, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Intranasal Oxytocin in Subjects With Chronic Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trigemina, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trigemina, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the use of oxytocin, given as a nasal spray, for treatment of high
      frequency episodic migraine and chronic migraine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change of migraine days</measure>
    <time_frame>Baseline and 28 days of treatment</time_frame>
    <description>Baseline is the 28-day screening period before study drug administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change of moderate or severe headache days</measure>
    <time_frame>Baseline and 28 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects experiencing a â‰¥50% reduction in migraine days</measure>
    <time_frame>Baseline and 28 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in days using rescue medication</measure>
    <time_frame>Baseline and 28 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects experiencing a reduction in headache severity and pain score 2 hours after dosing</measure>
    <time_frame>Baseline and 28 days of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>High Frequency Episodic Migraine and Chronic Migraine</condition>
  <arm_group>
    <arm_group_label>TI-001 (intranasal oxytocin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TI-001 is intranasal oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for TI-001 is the same intranasal formulation without oxytocin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TI-001</intervention_name>
    <description>TI-001 is intranasal oxytocin</description>
    <arm_group_label>TI-001 (intranasal oxytocin)</arm_group_label>
    <other_name>Intranasal oxytocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Men and women, aged 18 to 65 years with primary diagnosis of high frequency episodic
        migraine or chronic migraine.

        Exclusion Criteria:

          1. Known allergy to oxytocin

          2. History of addictive behavior (eg, alcoholism, drug abuse) or severe mood disorder

          3. History of clinically significant, functionally impairing cardiovascular or pulmonary
             disease or any other disease that might confound study results

          4. Have basilar or hemiplegic migraines

          5. Have substantial cognitive or memory impairment due to any cause (eg, Alzheimer's or
             dementia)

          6. Have a nasal obstruction due to any cause

          7. Are pregnant or breast feeding

          8. Require ongoing use of steroidal or nonsteroidal anti-inflammatory drugs

          9. Are unable or unwilling to provide informed consent or to follow study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raquel Izumi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Trigemina, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fitzroy</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prahran</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherwood</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Chile</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2013</study_first_submitted>
  <study_first_submitted_qc>April 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2013</study_first_posted>
  <last_update_submitted>May 11, 2016</last_update_submitted>
  <last_update_submitted_qc>May 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Refractory Chronic Migraine</keyword>
  <keyword>Medically Intractable Chronic Migraine</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Intranasal oxytocin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

